Szeged, Hungary

István Szatmári

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.7

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of István Szatmári

Introduction

István Szatmári is a notable inventor based in Szeged, Hungary. He has made significant contributions to the field of neuroprotective compounds and cancer treatment through his innovative patents. With a total of 2 patents, Szatmári's work focuses on developing pharmaceutical preparations that address critical health issues.

Latest Patents

Szatmári's latest patents include "Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity." This invention relates to C-3 substituted kynurenic acid derivatives that possess neuroprotective properties, potentially aiding in the prevention and treatment of neurodegeneration and cognitive decline. His second patent, "MDR-reversing 8-hydroxy-quinoline derivatives," focuses on 8-hydroxy-quinoline derivatives that exhibit multidrug-resistance reversing activity, specifically targeting multidrug-resistant cancer cells with improved selectivity and cytotoxicity.

Career Highlights

Throughout his career, Szatmári has worked with esteemed institutions such as Szeged University and the Hungarian Academy of Sciences, Natural Sciences Research Center. His research has contributed to advancements in pharmaceutical sciences and has the potential to impact the treatment of various diseases.

Collaborations

Szatmári has collaborated with notable colleagues, including Ferenc Fülöp and József Toldi. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

István Szatmári's contributions to the fields of neuroprotection and cancer treatment through his patents highlight his role as a significant inventor. His work continues to pave the way for advancements in medical science and offers hope for improved therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…